DENV1/DENV3 or 4

GTS1/3DP

2-1629

TRBV	CDR3	TRBJ	Freq (%)
11-2	CASSLGQGAYEQY	2-7	20.73
11-2	CASSYGTEQPQH	1-5	19.51
11-2	CASSLGGTDNEQF	2-1	14.63
11-2	CASSLGGDTYEQY	2-7	13.41
11-2	CASSLGVGPQWF	2-1	7.32
4-1	CASRRPREGLANEQF	2-1	6.10
15	CATSGRDRPNNEQF	2-1	4.88
12-3/4	CASSQTGATGELF	2-2	4.88
11-2	CASSLGPDYEQY	2-7	2.44
11-2	CASSLGAGGGSYEQY	2-7	1.22
11-2	CASSLEQGAYEQY	2-7	1.22
7-8	CASSPRGDGWEQY	2-7	1.22
11-2	CASSLQWGNEQF	2-1	1.22
11-2	CASSDGTEQPQH	1-5	1.22

2-1710

TRBV	CDR3	TRBJ	Freq (%)
12-3/4	CASSLGAPEAF	1-1	14.55
11/2	CASSLGQGTYEQY	2-7	10.91
11-2	CASSLGGQTYEQY	2-7	9.09
12-3/4	CASSLGAGVQETQY	2-5	5.45
7-3	CASSLAGVGNEQF	2-1	5.45
6-5	CASSYRGGRAGETQY	2-5	3.64
12-3/4	CASSLSAGGGTEAF	1-1	3.64
9	CASSQSGDRGEEQF	2-1	3.64
11-2	CASSVGQGEYEQY	2-7	3.64
11-3	CASSQGPDSPLH	1-6	3.64
11-2	CASSLGPENEQF	2-1	3.64
11-2	CASSLGPDQPQH	1-6	3.64
11-2	CASSHGPDSPLH	1-6	3.64
11-2	CASSLGPDEKLF	1-4	3.64
12-3/4	CASSAGAGELF	2-2	3.64
11-2	CASSLQPSGRGTDTQY	2-3	1.82
11-2	CASSLQPSGRGADTQY	2-3	1.82
7-3	CASSSVGGSGANVLT	2-6	1.82
11-2	CASSLLATLADTQY	2-3	1.82
11-2	CASSLLSGSSNEQF	2-1	1.82
7-8	CASSLTSGSTDTQY	2-3	1.82
29-1	CSVELSGINQPQH	1-5	1.82
11-2	CASSLGPEKEQF	2-1	1.82
12-3/4	CASSLGAGELF	2-2	1.82
12-3/4	CASSFGAGELF	2-2	1.82

2-1630

TRBV	CDR3	TRBJ	Freq (%)
11-2	CASSMGQGDYEQY	2-7	47.62
7-8	CASSPTGGGYEQY	2-7	45.24
11-2	CASSSGVNTGELF	2-2	4.76
11-2	CASSLGGTSGMGDGYEQY	2-7	1.19
11-2	CASSLVPSGTKNIQY	2-4	1.19

2-0664

TRBV	CDR3	TRBJ	Freq (%)
12-3/4	CASSFGAGSQETQY	2-5	5.48
11-2	CASSLGQGDFEQY	2-7	5.48
11-2	CASSPAGGTYEQY	2-7	5.48
11-2	CASSLGPEAPLF	1-4	5.48
10-3	CAISESMGTGTQETQY	2-5	4.11
11-2	CASSLGGSENEKLF	1-4	4.11
11-2	CASSLGGDTYEQY	2-7	4.11
11-2	CASSLGAGEYEQY	2-7	4.11
11-2	CASSLGQYTGELF	2-2	4.11
11-2	CASSLGTVSGMYTGELF	2-2	2.74
11-2	CASSFLPSGGPDYNEQF	2-1	2.74
11-2	CASSHNPGLPPYNEQF	2-1	2.74
9	CASSVDGDPSLDEQF	2-1	2.74
11-2	CASSLGAGTVGYEQY	2-7	2.74
11-2	CASSLGAGGAYEQY	2-7	2.74
11-2	CASSLGGGGAYEQY	2-7	2.74
9	CASSVSGDLGDTQY	2-3	2.74
11-2	CASSIGPDNEQF	2-1	2.74
12-3/4	CASSPGTTLGF	2-2	2.74
11-2	CASSLGPSGLSSYNEQF	2-1	1.37
11-2	CASSLVASGAISTDTQY	2-3	1.37
4-1	CASSQDPGLAGNEQF	2-1	1.37
11-2	CASSLGAGTSSYEQY	2-7	1.37
9	CASSATLASVTDTQY	2-3	1.37
11-2	CASSLGGTDYNEQF	2-1	1.37
11-2	CASSRIAGVYDEQF	2-1	1.37
29-1	CSVELGVAGVYEQY	2-7	1.37
11-2	CASSTGAGAPFGYT	1-2	1.37
11-2	CASSLGGTDNEQF	2-1	1.37
12-3/4	CASSLTQGGNTIY	1-3	1.37
12-3/4	CASSLGGAGNEQF	2-1	1.37
11-2	CASSLGLGLYEQY	2-7	1.37
11-2	CASSFDAGGNEQY	2-7	1.37
11-2	CASSLGPYVDTQY	2-3	1.37
11-2	CASSLGQGAYEQY	2-7	1.37
9	CASSGGDVREEQY	2-7	1.37
12-3/4	CASSAGSGNEQY	2-7	1.37
11-2	CASSLGPDNEQF	2-1	1.37
11-2	CASSLGPDSPLH	1-6	1.37
11-2	CASSLSPEYEQY	2-7	1.37
12-3/4	CASSLGTTEAF	1-1	1.37

2-0573

TRBV	CDR3	TRBJ	Freq (%)
27	CASLSGRAPQH	1-5	45.78
11-2	CASSLVIIGSASTDTQY	2-3	33.73
11-2	CASSLQPSGTSFYNEQF	2-1	14.46
12-3/4	CASSLGTREAF	1-1	6.02

Supplementary Figure 3 TRBV and TRBJ usage, CDR3β amino acid sequence, and clonotype frequency are shown for $CD3^{+}CD8^{+}CD14^{-}CD19^{-}$ HLA-A*11:01-GTS1 and HLA-A*11:01-GTS3/4 $tetramer^{+}$ populations isolated from patients sequentially infected with various combinations of DENV1/3/4. Recurrent clonotypes are highlighted in color. DP, double positive; GTS3, GTS3/4 (blue type).